Trevi Therapeutics (NASDAQ:TRVI - Get Free Report)'s stock had its "buy" rating reiterated by analysts at D. Boral Capital in a research note issued on Wednesday,Benzinga reports. They presently have a $21.00 price target on the stock. D. Boral Capital's price target suggests a potential upside of 224.57% from the company's previous close.
TRVI has been the subject of a number of other research reports. Needham & Company LLC reduced their price target on Trevi Therapeutics from $25.00 to $24.00 and set a "buy" rating for the company in a report on Wednesday. HC Wainwright increased their price target on Trevi Therapeutics from $7.50 to $12.50 and gave the company a "buy" rating in a report on Monday, March 10th. Raymond James raised Trevi Therapeutics from an "outperform" rating to a "strong-buy" rating and increased their price target for the company from $9.00 to $29.00 in a report on Monday, March 10th. Finally, Oppenheimer increased their price target on Trevi Therapeutics from $12.00 to $20.00 and gave the company an "outperform" rating in a report on Tuesday, March 11th. Seven analysts have rated the stock with a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Buy" and an average target price of $17.56.
Get Our Latest Analysis on Trevi Therapeutics
Trevi Therapeutics Stock Down 2.1 %
Shares of NASDAQ TRVI traded down $0.14 on Wednesday, hitting $6.47. The company had a trading volume of 3,742,537 shares, compared to its average volume of 994,524. Trevi Therapeutics has a 12-month low of $2.30 and a 12-month high of $7.39. The business has a 50 day moving average of $4.60 and a two-hundred day moving average of $3.76. The firm has a market capitalization of $497.32 million, a P/E ratio of -14.70 and a beta of 0.90.
Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last issued its earnings results on Tuesday, March 18th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.01. On average, sell-side analysts anticipate that Trevi Therapeutics will post -0.49 earnings per share for the current year.
Insiders Place Their Bets
In other Trevi Therapeutics news, insider Farrell Simon sold 81,313 shares of the stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $6.75, for a total transaction of $548,862.75. Following the transaction, the insider now owns 76,900 shares of the company's stock, valued at $519,075. This trade represents a 51.39 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 24.37% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of the company. Frazier Life Sciences Management L.P. raised its position in shares of Trevi Therapeutics by 44.5% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 10,664,774 shares of the company's stock worth $43,939,000 after purchasing an additional 3,283,684 shares during the period. Point72 Asset Management L.P. acquired a new stake in shares of Trevi Therapeutics during the 4th quarter worth approximately $17,099,000. Vivo Capital LLC raised its position in shares of Trevi Therapeutics by 116.3% during the 4th quarter. Vivo Capital LLC now owns 3,487,903 shares of the company's stock worth $14,370,000 after purchasing an additional 1,875,000 shares during the period. Woodline Partners LP raised its position in shares of Trevi Therapeutics by 429.9% during the 4th quarter. Woodline Partners LP now owns 3,212,597 shares of the company's stock worth $13,236,000 after purchasing an additional 2,606,370 shares during the period. Finally, MPM Bioimpact LLC raised its position in shares of Trevi Therapeutics by 101.2% during the 4th quarter. MPM Bioimpact LLC now owns 3,094,896 shares of the company's stock worth $12,751,000 after purchasing an additional 1,556,379 shares during the period. Institutional investors own 95.76% of the company's stock.
About Trevi Therapeutics
(
Get Free Report)
Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.
Further Reading
Before you consider Trevi Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Trevi Therapeutics wasn't on the list.
While Trevi Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
